- Home
- DDD vs AURA Comparison
DDD vs AURA Comparison
Compare DDD & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DDD
- AURA
- Stock Information
- Founded
- DDD 1986
- AURA 2007
- Country
- DDD United States
- AURA United States
- Employees
- DDD N/A
- AURA N/A
- Industry
- DDD Computer peripheral equipment
- AURA Biotechnology: Pharmaceutical Preparations
- Sector
- DDD Technology
- AURA Health Care
- Exchange
- DDD Nasdaq
- AURA Nasdaq
- Market Cap
- DDD 344.6M
- AURA 370.1M
- IPO Year
- DDD N/A
- AURA 2021
- Fundamental
- Price
- DDD $2.11
- AURA $5.86
- Analyst Decision
- DDD Hold
- AURA Strong Buy
- Analyst Count
- DDD 3
- AURA 4
- Target Price
- DDD $3.50
- AURA $22.75
- AVG Volume (30 Days)
- DDD 3.0M
- AURA 380.1K
- Earning Date
- DDD 03-26-2025
- AURA 03-24-2025
- Dividend Yield
- DDD N/A
- AURA N/A
- EPS Growth
- DDD N/A
- AURA N/A
- EPS
- DDD N/A
- AURA N/A
- Revenue
- DDD $440,121,000.00
- AURA N/A
- Revenue This Year
- DDD $6.02
- AURA N/A
- Revenue Next Year
- DDD $13.35
- AURA N/A
- P/E Ratio
- DDD N/A
- AURA N/A
- Revenue Growth
- DDD N/A
- AURA N/A
- 52 Week Low
- DDD $1.72
- AURA $5.72
- 52 Week High
- DDD $5.00
- AURA $12.38
- Technical
- Relative Strength Index (RSI)
- DDD 26.43
- AURA 29.89
- Support Level
- DDD $2.43
- AURA $5.77
- Resistance Level
- DDD $2.82
- AURA $6.36
- Average True Range (ATR)
- DDD 0.17
- AURA 0.47
- MACD
- DDD -0.03
- AURA -0.15
- Stochastic Oscillator
- DDD 10.56
- AURA 6.97
About DDD 3D Systems Corporation
3D Systems Corp provides comprehensive 3D printing and digital manufacturing solutions, including 3D printers for plastics and metals, materials, software, on-demand manufacturing services, and digital design tools. The company's segments include Healthcare Solutions and Industrial Solutions. It generates maximum revenue from the Industrial segment. It conducts business through various offices and facilities located throughout the Americas, EMEA, and APAC; generating a vast majority of revenues from the Americas.
About AURA Aura Biosciences Inc.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its lead candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.